ANDA 204221, held by Zydus Pharms. Hydrochlorothiazide; Telmisartan.
As of Nov 16, 2026, ANDA 204221 (Telmisartan And Hydrochlorothiazide), held by Zydus Pharms, was first approved by FDA on Aug 15, 2017, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 15, 2017 | Original application | Approved | None posted |
| Telmisartan And Hydrochlorothiazide12.5MG;40MG · tablet;oral | Hydrochlorothiazide; Telmisartan | Rx |
| Telmisartan And Hydrochlorothiazide12.5MG;80MG · tablet;oral | Hydrochlorothiazide; Telmisartan | Rx |
| Telmisartan And Hydrochlorothiazide25MG;80MG · tablet;oral | Hydrochlorothiazide; Telmisartan | Rx |
| Dec 10, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 6, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 15, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters